VIRGINIA RETIREMENT SYSTEMS ET Al Acquires Shares of 92,218 IDEXX Laboratories, Inc. $IDXX

Key Points

• Virginia Retirement Systems acquired 92,218 shares of IDEXX Laboratories in the second quarter, valued at approximately $48.5 million, giving it a 0.12% stake. Institutional investors and hedge funds collectively own 87.84% of the company.
• IDEXX reported quarterly earnings of $4.27 per share, exceeding the $3.94 analyst consensus, while revenue reached $1.22 billion and rose 9.7% year over year. The company reaffirmed fiscal 2026 EPS guidance of $14.69 to $14.94.
• The stock opened at $535.38, well below its 52-week high of $769.98. Analysts maintain a “Moderate Buy” consensus with a $747 price target, despite some recent rating downgrades and reduced price objectives.

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 92,218 shares of the company's stock, valued at approximately $48,547,000. VIRGINIA RETIREMENT SYSTEMS ET Al owned about 0.12% of IDEXX Laboratories at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the stock. SHP Wealth Management acquired a new stake in shares of IDEXX Laboratories in the fourth quarter valued at approximately $26,000. Virtus Advisers LLC acquired a new position in IDEXX Laboratories during the 3rd quarter worth $26,000. J.Safra Asset Management Corp bought a new position in IDEXX Laboratories in the 2nd quarter valued at $25,000. Elevation Wealth Partners LLC boosted its position in IDEXX Laboratories by 188.2% in the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company's stock valued at $26,000 after buying an additional 32 shares during the last quarter. Finally, Wormser Freres Gestion increased its stake in shares of IDEXX Laboratories by 671.4% in the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company's stock valued at $37,000 after buying an additional 47 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $535.38 on Monday. The firm has a fifty day moving average of $558.27 and a two-hundred day moving average of $570.05. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. The stock has a market capitalization of $42.18 billion, a price-to-earnings ratio of 37.65, a PEG ratio of 2.86 and a beta of 1.54. IDEXX Laboratories, Inc. has a 52 week low of $518.55 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, topping analysts' consensus estimates of $3.94 by $0.33. The business had revenue of $1.22 billion during the quarter, compared to analysts' expectations of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The firm's quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

Analyst Upgrades and Downgrades

IDXX has been the subject of a number of recent research reports. Wall Street Zen downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Sunday, July 12th. Citigroup raised their price target on IDEXX Laboratories from $650.00 to $670.00 and gave the company a "neutral" rating in a report on Wednesday, August 5th. Weiss Ratings lowered IDEXX Laboratories from a "hold (c+)" rating to a "hold (c)" rating in a research report on Thursday, August 27th. Barclays dropped their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating for the company in a report on Tuesday, August 11th. Finally, UBS Group upped their target price on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the company a "neutral" rating in a research report on Wednesday, August 5th. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $747.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.